A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn's Disease.
Latest Information Update: 17 Apr 2026
At a glance
- Drugs AZD 7798 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 14 Apr 2026 Status changed from active, no longer recruiting to completed.
- 03 Dec 2025 Planned End Date changed from 14 Aug 2026 to 16 Apr 2026.
- 03 Dec 2025 Planned primary completion date changed from 14 Aug 2026 to 16 Apr 2026.